← Back to Search

Meaning-Centered Supportive Care for Advanced Cancer

N/A
Waitlist Available
Led By Francesca Gany, MD, PhD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
To assess English proficiency, participants will be asked two questions: (1) the Census limited English proficient item 'How well do you speak English?' with response options 'Not at all, Not well, Well, or Very well' and (2) 'What is your preferred language for healthcare?'
Participants who are eligible for the study and are fluent in English will be identified by the response 'Very well' to the 1st question and a response indicating English as the preferred language for healthcare.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial will compare two different types of supportive care for Muslim patients with advanced cancer. One intervention is based on faith, and the other is not.

Who is the study for?
This trial is for adult Muslim patients with stage III or IV cancer who are currently in treatment. They must have a life expectancy of at least 6 months, be cognitively intact, and able to speak and read English or Arabic. Excluded are those with major psychiatric illnesses, primary brain tumors, undergoing stem cell transplantation, or currently in psychotherapy.Check my eligibility
What is being tested?
The study compares Masterful supportive care tailored for Muslims against non-faith-based control care using American Cancer Society materials. Participants will undergo three sessions which can be spread out over one week or up to 12 weeks based on their preference.See study design
What are the potential side effects?
Since the interventions involve supportive care rather than medical treatments, traditional side effects like those seen with medications are not expected. However, emotional distress related to discussing advanced cancer may occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can communicate in English or have a preferred language for healthcare.
Select...
I speak English very well and prefer it for my healthcare.
Select...
I am currently being treated or monitored for stage III or IV cancer.
Select...
My thinking and memory skills are considered normal by my doctor.
Select...
I am 18 years old or older.
Select...
I can speak and read either English or Arabic.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
number of enrolled participants completing at least one psychotherapy session out of the planned three.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Masterful supportive careExperimental Treatment1 Intervention
This intervention uses teachings, discussions, and exercises about personal experiences that focus on specific topics related to meaning and cancer. For example, we may discuss what is meaningful in your life, how you identify yourself before and after cancer, and your hopes for the future. The Masterful intervention is available in both English and Arabic, and it will be delivered by a trained bilingual member of the study team. It includes 3 weekly (or at participant's preference) 1-hour sessions with a member of the study team. The sessions for either the treatment or the control arm will take place in-person in a private room at MSKCC or via teleconference, depending on the patients preference. Meeting one-on-one with an interventionist was feasible in our pilot study and will enhance relationship-building between interventionist and patient. Participants will have the option to meet with the interventionist via teleconference in order to reduce in-person contact burden.
Group II: Attention control supportive careActive Control1 Intervention
This intervention uses the American Cancer Society's patient education materials. These sessions will include discussions about managing a self-identified current problem in your life. The attention control supportive care intervention is available in both English and Arabic, and it will be delivered by a trained bilingual member of the study team. It includes 3 weekly (or at participant's preference) 1-hour sessions with a member of the study team. The sessions for either the treatment or the control arm will take place in-person in a private room at MSKCC or via teleconference, depending on the patients preference. Meeting one-on-one with an interventionist was feasible in our pilot study and will enhance relationship-building between interventionist and patient. Participants will have the option to meet with the interventionist via teleconference in order to reduce in-person contact burden.

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,930 Previous Clinical Trials
597,268 Total Patients Enrolled
UConn HealthOTHER
211 Previous Clinical Trials
60,602 Total Patients Enrolled
Francesca Gany, MD, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Media Library

Attention control supportive care Clinical Trial Eligibility Overview. Trial Name: NCT04435444 — N/A
Cancer Research Study Groups: Attention control supportive care, Masterful supportive care
Cancer Clinical Trial 2023: Attention control supportive care Highlights & Side Effects. Trial Name: NCT04435444 — N/A
Attention control supportive care 2023 Treatment Timeline for Medical Study. Trial Name: NCT04435444 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any additional slots accessible to prospective participants in this medical experiment?

"From the information on clinicaltrials.gov, it appears that this medical trial is currently not accepting new participants as its most recent update was from December 28th 2021. However, there are 2469 other trials seeking volunteers at present."

Answered by AI
~1 spots leftby Jun 2024